{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:51:58Z","timestamp":1791805918918,"version":"4.3.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nippon Shinyaku Co., Ltd."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0240692","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T18:49:02Z","timestamp":1602787742000},"page":"e0240692","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416\/hypoxia-induced pulmonary arterial hypertension in rats"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-4343","authenticated-orcid":true,"given":"Yohei","family":"Honda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Fuchikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kuramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Numakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"pone.0240692.ref001","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: Pulmonary arterial hypertension","author":"RT Schermuly","year":"2011","journal-title":"Nature Reviews Cardiology"},{"key":"pone.0240692.ref002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1165\/rcmb.2009-0389TR","article-title":"Reversible or irreversible remodeling in pulmonary arterial hypertension","volume":"43","author":"S Sakao","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"pone.0240692.ref003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":"Prostacyclin and its analogues in the treatment of pulmonary hypertension","author":"H Olschewski","year":"2004","journal-title":"Pharmacology and Therapeutics"},{"key":"pone.0240692.ref004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"RJ Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"pone.0240692.ref005","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"NW Morrell","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"pone.0240692.ref006","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: An oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"58","author":"T Asaki","year":"2015","journal-title":"J Med Chem"},{"key":"pone.0240692.ref007","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"O Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0240692.ref008","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"N Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"pone.0240692.ref009","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1165\/rcmb.2010-0371OC","article-title":"Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats","volume":"45","author":"K Abe","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"pone.0240692.ref010","doi-asserted-by":"crossref","first-page":"L523","DOI":"10.1152\/ajplung.00129.2014","article-title":"Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis","volume":"308","author":"T Shinohara","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"pone.0240692.ref011","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.201607-1515PP","article-title":"Translating research into improved patient care in pulmonary arterial hypertension","volume":"195","author":"S Bonnet","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0240692.ref012","doi-asserted-by":"crossref","first-page":"eaao0303","DOI":"10.1126\/scitranslmed.aao0303","article-title":"PPAR\u03b3 agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation","volume":"10","author":"E Legchenko","year":"2018","journal-title":"Sci Transl Med"},{"key":"pone.0240692.ref013","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201910-1983LE","article-title":"The adult sprague-dawley sugen-hypoxia rat is still \u201cthe One:\u201d A model of group 1 pulmonary hypertension: Reply to le cras and abman","volume":"201","author":"HJ Bogaard","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0240692.ref014","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1164\/rccm.201906-1200LE","article-title":"Emphysema is-at the most-only a mild phenotype in the sugen\/hypoxia rat model of pulmonary arterial hypertension","volume":"200","author":"HJ Bogaard","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0240692.ref015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1183\/09031936.00188013","article-title":"Iloprost reverses established fibrosis in experimental right ventricular failure","volume":"45","author":"J Gomez-Arroyo","year":"2015","journal-title":"Eur Respir J"},{"key":"pone.0240692.ref016","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/bph.14472","article-title":"Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling","volume":"175","author":"KR Chaudhary","year":"2018","journal-title":"Br J Pharmacol"},{"key":"pone.0240692.ref017","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2016.11.057","article-title":"A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries","volume":"795","author":"C Fuchikami","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"pone.0240692.ref018","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"K Abe","year":"2010","journal-title":"Circulation"},{"key":"pone.0240692.ref019","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.RES.0000261658.12024.18","article-title":"Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats","volume":"100","author":"M Oka","year":"2007","journal-title":"Circ Res"},{"key":"pone.0240692.ref020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3892\/ijmm.2015.2110","article-title":"Effects of baicalin on collagen \u0399 and collagen \u0399\u0399\u0399 expression in pulmonary arteries of rats with hypoxic pulmonary hypertension","volume":"35","author":"P Liu","year":"2015","journal-title":"Int J Mol Med"},{"key":"pone.0240692.ref021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.fertnstert.2017.01.005","article-title":"Important role of collective cell migration and nerve fiber density in the development of deep nodular endometriosis","volume":"107","author":"R Orellana","year":"2017","journal-title":"Fertil Steril"},{"key":"pone.0240692.ref022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"N Nakahata","year":"2008","journal-title":"Pharmacol Ther"},{"key":"pone.0240692.ref023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"BW Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"pone.0240692.ref024","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0306-3623(95)00025-9","article-title":"Thromboxane A2 receptor-mediated signal transduction in rabbit aortic smooth muscle cells","volume":"26","author":"K Yamamoto","year":"1995","journal-title":"Gen Pharmacol"},{"key":"pone.0240692.ref025","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1152\/ajplung.00042.2008","article-title":"Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat","volume":"295","author":"AM Badejo","year":"2008","journal-title":"Am J Physiol\u2014Lung Cell Mol Physiol"},{"key":"pone.0240692.ref026","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1152\/ajpheart.00953.2010","article-title":"Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60\u20132770, are not dependent on endogenous nitric oxide or reduced heme","volume":"300","author":"EA Pankey","year":"2011","journal-title":"Am J Physiol\u2014Hear Circ Physiol"},{"key":"pone.0240692.ref027","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"322","author":"K Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0240692.ref028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"E Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0240692.ref029","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1164\/ajrccm.162.4.9912131","article-title":"Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: A morphometric and immunohistochemical study","volume":"162","author":"ES Yi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0240692.ref030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1124\/jpet.108.138305","article-title":"A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on rat pulmonary artery","volume":"326","author":"K Kuwano","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0240692.ref031","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1016\/j.bmc.2007.08.052","article-title":"Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist","volume":"15","author":"A Nakamura","year":"2007","journal-title":"Bioorganic Med Chem"},{"key":"pone.0240692.ref032","doi-asserted-by":"crossref","first-page":"L899","DOI":"10.1152\/ajplung.00527.2016","article-title":"Endothelial cell-related autophagic pathways in Sugen\/hypoxia-exposed pulmonary arterial hypertensive rats","volume":"313","author":"F Kato","year":"2017","journal-title":"Am J Physiol\u2014Lung Cell Mol Physiol"},{"key":"pone.0240692.ref033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40256-015-0117-4","article-title":"Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag","volume":"15","author":"P Kaufmann","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0240692.ref034","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"G Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"pone.0240692.ref035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/cvr\/cvw070","article-title":"Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension","volume":"111","author":"K Abe","year":"2016","journal-title":"Cardiovasc Res"},{"key":"pone.0240692.ref036","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/jpet.116.239665","article-title":"Selexipag active metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low \u03b2-arrestin recruitment and desensitization potential","volume":"362","author":"J Gatfield","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0240692.ref037","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1253\/circj.CJ-17-0139","article-title":"Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension","volume":"82","author":"Y Tamura","year":"2018","journal-title":"Circ J"},{"key":"pone.0240692.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180455","article-title":"Contribution of reactive oxygen species to the pathogenesis of pulmonary arterial hypertension","volume":"12","author":"NL Jernigan","year":"2017","journal-title":"PLoS One"},{"key":"pone.0240692.ref039","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1164\/rccm.201403-0483OC","article-title":"Sex-dependent influence of endogenous estrogen in pulmonary hypertension","volume":"190","author":"KM Mair","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0240692.ref040","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"M Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"pone.0240692.ref041","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1165\/rcmb.2018-0142OC","article-title":"The antifibrotic activity of prostacyclin receptor agonism is mediated through inhibition of YAP\/TAZ","volume":"60","author":"K Zmajkovicova","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"pone.0240692.ref042","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: Results from a national prospective registry","volume":"115","author":"GE D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"pone.0240692.ref043","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1183\/09031936.00046612","article-title":"Pathobiology of pulmonary arterial hypertension and right ventricular failure","author":"NF Voelkel","year":"2012","journal-title":"European Respiratory Journal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T18:49:19Z","timestamp":1602787759000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240692"}},"subtitle":[],"editor":[{"given":"Michael","family":"Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0240692","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}